Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4Plasma cell 2Other hematologic neoplasm 1Gynecologic 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

venetoclax 190Cyclophosphamide 124Azacitidine 112Cytarabine 108fludarabine 92Specimen Handling 75Biopsy 54Daunorubicin 42Methotrexate 40Dexamethasone 37Rituximab 34blinatumomab 32Vincristine 31Decitabine 31fludarabine phosphate 30Injections 28Granulocyte Colony-Stimulating Factor 28Magnetic Resonance Spectroscopy 27Whole-Body Irradiation 26obinutuzumab 25Idarubicin 25acalabrutinib 23Mycophenolic Acid 23Prednisone 22Melphalan 21Busulfan 21gilteritinib 19Stem Cell Transplantation 19Doxorubicin 19ibrutinib 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Hyaluronoglucosaminidase × Other hematologic neoplasm × Clear all
NCT05289687 2026-05-05

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Eastern Cooperative Oncology Group

Phase 2 Recruiting
20 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡